CLINICAL_TRIALS
trial_result
· 2011-06-14
Clinical Trial Update: Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer [Phase 2]
Summary
A Phase 2 trial evaluating daily 37.5 mg sunitinib malate in patients with advanced renal cell carcinoma; results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Carcinoma, Renal Cell | Phase 2 | Status: COMPLETED | Results posted: 2011-06-14